within Pharmacolibrary.Drugs.ATC.C;

model C08EX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.35,
    Cl             = 0.96 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,
    adminCount     = 1,
    Vd             = 0.02,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Perhexiline is an antianginal agent that inhibits carnitine palmitoyltransferase-1 and -2, thereby modulating cardiac metabolism. It was used for the management of angina pectoris and some other cardiovascular indications but its use dropped sharply due to concerns of hepatotoxicity and neuropathy; in some countries it remains available under restricted conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in adult patients with angina pectoris, after oral administration, steady-state, mixed male and female, normal hepatic and renal function.</p><h4>References</h4><ol><li><p>Gould, BJ, et al., &amp; Parke, DV (1986). Stereoselective pharmacokinetics of perhexiline. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 16(5) 491–502. DOI:<a href=&quot;https://doi.org/10.3109/00498258609050254&quot;>10.3109/00498258609050254</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3739369/&quot;>https://pubmed.ncbi.nlm.nih.gov/3739369</a></p></li><li><p>Davies, BJ, et al., &amp; Sallustio, BC (2008). Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline. <i>British journal of clinical pharmacology</i> 65(3) 347–354. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2007.03015.x&quot;>10.1111/j.1365-2125.2007.03015.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17875193/&quot;>https://pubmed.ncbi.nlm.nih.gov/17875193</a></p></li><li><p>Sallustio, BC, et al., &amp; Morris, RG (2002). Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. <i>British journal of clinical pharmacology</i> 54(2) 107–114. DOI:<a href=&quot;https://doi.org/10.1046/j.1365-2125.2002.01618.x&quot;>10.1046/j.1365-2125.2002.01618.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12207628/&quot;>https://pubmed.ncbi.nlm.nih.gov/12207628</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C08EX02;
